However, whether glucagon-like peptide-1 receptor agonists (GLP-1RAs), a class of diabetes medication which causes weight loss, reduce cancer incidence is unknown. This study investigated whether ...

Background: The use of glucagon-like peptide 1 receptor agonists (GLP-1RAs) has substantially expended given their remarkable benefits in managing obesity. Yet, their impact on long-term cancer risk ...

About The Study: In this cohort study, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among patients with diabetes was associated with a 2-fold higher risk of incident ...

The UK's health regulator is investigating Ozempic and Mounjaro after linking the drugs to hundreds of severe illnesses and ...

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

Patients with type 2 diabetes had a lower risk of glaucoma when they used glucagon-like peptide 1 (GLP-1) receptor agonists ...

Mumbai: Novo Nordisk, a global healthcare company headquartered in Denmark, has announced the launch of Wegovy (injectable ...

BARCELONA -- A rheumatology trainee who went on TikTok to find information on her own condition may have uncovered a novel ...

A common diabetes drug may be the next big thing for migraine relief. In a clinical study, obese patients with chronic ...

New research links semaglutide and tirzepatide, which are GLP-1 agonists used to treat type 2 diabetes and aid weight loss, ...

A new study finds that the diabetes drug liraglutide significantly reduced monthly migraine days in patients with obesity and ...